1. Home
  2. MESO vs DHC Comparison

MESO vs DHC Comparison

Compare MESO & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.39

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

HOLD

Current Price

$7.60

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MESO
DHC
Founded
2004
1998
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2005
1998

Fundamental Metrics

Financial Performance
Metric
MESO
DHC
Price
$16.39
$7.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
180.2K
1.3M
Earning Date
02-26-2026
05-04-2026
Dividend Yield
N/A
0.53%
EPS Growth
N/A
23.23
EPS
N/A
N/A
Revenue
N/A
$1,074,819,000.00
Revenue This Year
$629.74
$3.13
Revenue Next Year
$30.65
$7.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.59
52 Week Low
$13.05
$3.93
52 Week High
$21.50
$9.66

Technical Indicators

Market Signals
Indicator
MESO
DHC
Relative Strength Index (RSI) 48.95 35.18
Support Level $15.37 $6.92
Resistance Level $17.10 $9.66
Average True Range (ATR) 0.44 0.24
MACD -0.09 -0.01
Stochastic Oscillator 1.06 25.86

Price Performance

Historical Comparison
MESO
DHC

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.

Share on Social Networks: